
Sponsors

University of Minnesota

College of Veterinary Medicine

College of Agricultural, Food and Environmental Sciences

Extension Service

Swine Center

Editors

W. Christopher Scruton

Stephen Claas

Layout

David Brown

Logo Design

Ruth Cronje, and Jan Swanson;

based on the original design by Dr. Robert Dunlop

Cover Design

Shawn Welch

The University of Minnesota is committed to the policy that all persons shall have equal access to its programs, facilities, and employment without regard to race, color, creed, religion, national origin, sex, age, marital status, disability, public assistance status, or sexual orientation.

Efficacy evaluation of Enterisol® SC-54 in swine following challenge with a virulent *S. typhimurium* strain

Axel Neubauer and Michael B. Roof

Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO, USA

Introduction

According to a Center of Disease Control and Prevention estimate, 1.4 million individuals in the US suffer from Salmonella-associated disease every year¹. The most important serovar in this context is *S. typhimurium*, which accounts for 21.9% of all Salmonella isolates. *S. typhimurium* is also the most frequently isolated serovar from clinical pig samples². As pork products are frequently associated with clinical Salmonellosis in humans³, *S. typhimurium* control in pigs is an important food safety issue. Whereas *S. typhimurium* can cause enterocolitis in pigs, the majority of infections prevail subclinically resulting in substantial economic losses due to a reduction in daily weight gain⁴. The purpose of this study was to determine if Enterisol SC-54, which is based on an attenuated *S. cholerasuis* strain, can be used to control *S. typhimurium* in pigs.

Materials and Methods

The study consisted of 3 groups. Group 1 (21 animals) was vaccinated at day 0 with 2 mL Enterisol SC-54. At day 28, group 1 and group 2 (21 animals; challenge control) were challenged with 2 mL virulent *S. typhimurium* (BIVI 02-04) culture. Group 3 (20 animals) served as strict control. Criteria to determine protection included display of clinical symptoms, weight gain, fecal shedding of Salmonella, and the results of the pathological examination (presence of gross-lesions, colonization of inner organs by Salmonella), which was conducted two weeks after challenge. Shedding of the vaccine strain and seroconversion (IDEXX Salmonella Herd Check™) were monitored. The data was analyzed using a SAS environment. Applied tests included ANOVA and Chi-Square/Fisher's Exact analysis.

Results and Discussion

Compared to the non-vaccinated challenge control group, the Enterisol SC-54 group showed significantly ($p \leq 0.05$) fewer clinical symptoms relevant to their general well-being. There was also a significant ($p \leq 0.05$) reduction in the prevalence of respiratory symptoms, loose feces/diarrhea, and decreased hydration. A significant ($p \leq 0.05$) reduction in the prevalence of enteropathy/enteritis affecting the small intestine, as well as a significant ($P \leq 0.05$) reduction of the Salmonella recovery rate from the mesenteric lymph node compared to the non-vaccinated pigs was also observed in

the Enterisol SC-54 vaccinated animals. A summary of these results is given in table 1.

Table 1: Statistical significant differences between groups regarding clinical, pathological, and bacteriological findings.

	Enterisol® SC-54	Challenge Control	Strict Control
	positive findings in %		
impaired GWB ¹⁾	2.25*	7.64	0.00
respiratory symptoms	0.00*	5.05	0.00
decreased hydration	0.78*	4.80	0.00
loose feces/diarrhea	9.71*	19.43	0.00
enteropathy/enteritis ²⁾	10.00*	73.33	35.29
Salmonella recovery MLN ³⁾	36.84*	73.33	0.00

¹⁾Differences between Enterisol SC-54 and Challenge Control groups are statistical significant ($p \leq 0.05$; Chi-Square/Fischer's Exact analysis); ¹⁾GWB=General well-being; ²⁾affecting the small intestine; ³⁾MLN=mesenteric lymph node

In addition, the vaccinated animals showed a significant ($p \leq 0.05$) increase in average daily weight gain post-challenge (days 27-42) and a significantly ($p \leq 0.05$) higher weight at the end of the trial (day 42) compared to the challenge control group. The results are listed in table 2.

Table 2: Statistical significant differences between groups regarding weight and weight gain.

	Enterisol® SC-54	Challenge Control	Strict Control
Day 42 weight	62.10 lbs.* ¹⁾	57.67 lbs.	68.56 lbs.
ADWG 27 to 42 ²⁾	1.07 lbs.*	0.85 lbs.	1.36 lbs.

¹⁾Differences between Enterisol SC-54 and Challenge Control groups are statistical significant ($p \leq 0.05$; Chi-Square/Fischer's Exact analysis); ¹⁾all values are group means ²⁾ADWG - Average daily weight gain between challenge and necropsy dates (trial day 27- 42)

Fecal shedding post-challenge, however, could not be prevented by vaccination. One of the vaccinated animals died of Salmonellosis after challenge, compared to four animals in the challenge control group. The animals did not sero-convert following immunization. Statistical significant shedding of the vaccine strain was not observed in the Enterisol SC-54 animals compared to the non-vaccinated controls. The results of this study demonstrated that vaccination with Enterisol SC-54 resulted in significant levels of protection following challenge with a virulent *S. typhimurium* strain. This indicates that Enterisol SC-54 can be a valuable asset in the control of *S. typhimurium*-associated clinical and subclinical symptoms. Vaccination with Enterisol SC-54 does at the same time not impair serological evaluation of individual animals or whole herds due to the lack of detectable seroconversion following immunization. Enterisol SC-54 also seems to be an appropriate tool for food-safety management due to the effect on *S. typhimurium* colonization in the carcass as demonstrated by the reduction of mesenteric lymph node colonization.

References

- ¹ Mead PS et al. Food related illness and death in the United States. Emerg Infect Dis. 1999:607-625.
- ² CDC. Salmonella Surveillance Summary, 2002. Atlanta, Georgia: US Department of Health and Human Services, CDC, 2003.
- ³ Steinbach G, Hartung M. [Attempt to estimate the share of human Salmonella infections, which are attributable to Salmonella originating from swine] Berl Munch Tierarztl Wochenschr. 1999:296-300
- ⁴ Nielsen JN et al. Productivity and Salmonella incidence of swine reared in differing management systems. Purdue University 1997 Swine Day Report.